A Canadian medical device company is seeking a strategic partner to accelerate global commercialization of a patented mobility and patient-transfer system used in institutional healthcare settings (hospitals, long-term care homes, rehabilitation centers). The company's flagship product is a durable medical device that functions as an accessory to a wheelchair, purpose-built for institutional healthcare settings including hospitals, long-term care homes, and rehabilitation centers. It addresses a large and growing market driven by aging populations, chronic caregiver and clinical staffing shortages, and a sector-wide push toward fall prevention and safer patient mobility. The device has no direct competitor offering the same combination of benefits, and has shown fast-growing commercial traction since launch, with expansion opportunities across additional care settings, geographies, and complementary product lines. Key Highlights: - First-to-market design. No directly comparable product exists in the transfer-and-ambulation device category — the only solution combining active walking support and wheelchair transfer in a single mobile platform, with single-clinician operation. - Defensible IP position. Granted utility patents in North America providing protection throughredactedAn active international patent application (PCT) preserves rights across 150+ countries, with a filing election deadline in mid-2027 — creating a time-sensitive window for a buyer seeking global rights. - Clinically validated. Multi-site clinical trials in partnership with Canadian universities and hospital systems demonstrated meaningful, double-digit percentage improvements across multiple patient mobility and confidence outcomes. - Regulatory cleared. Health Canada approved; Class I exempt status under the FDA framework, positioning the product for near-term US market entry. - Early commercial traction. Strong initial unit sales across multiple Canadian provinces within the first year of commercialization, with several active B2B distributor relationships already in place and approvals with major national healthcare group purchasing organizations. - Strong unit economics. Manufactured under ISO 9001 & GMP-compliant production with a landed cost representing a small fraction of distributor and retail pricing — supporting gross margins in the mid-80% range. - Institutional research validation. The company is engaged in a funded, multi-site evaluation study with an institutional healthcare partner, generating clinical and economic evidence to support broader procurement adoption. - Platform for growth. The core product is designed as an expandable platform, with several accessory add-ons already identified on the product roadmap. - Significant non-dilutive validation. The company has earned meaningful competitive awards and research grant funding across numerous programs, reflecting strong third-party and institutional credibility. Deal Structure: The company is open to a full acquisition, or a standalone IP/licensing arrangement for the right party. Flexible to align with the strategic objectives of the right counterparty. Next Steps: Qualified parties who execute a non-disclosure agreement will receive further information.